DexCom, Inc. $DXCM Stock Holdings Increased by Apollon Wealth Management LLC

Apollon Wealth Management LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 7.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,196 shares of the medical device company’s stock after purchasing an additional 1,526 shares during the quarter. Apollon Wealth Management LLC’s holdings in DexCom were worth $1,850,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. Fulcrum Capital LLC raised its position in DexCom by 11.2% during the second quarter. Fulcrum Capital LLC now owns 37,881 shares of the medical device company’s stock valued at $3,307,000 after acquiring an additional 3,809 shares in the last quarter. DSM Capital Partners LLC raised its position in DexCom by 252.1% during the second quarter. DSM Capital Partners LLC now owns 1,435,296 shares of the medical device company’s stock valued at $125,287,000 after acquiring an additional 1,027,633 shares in the last quarter. Inspire Investing LLC bought a new position in DexCom during the second quarter valued at approximately $258,000. Commerzbank Aktiengesellschaft FI bought a new position in DexCom during the second quarter valued at approximately $252,000. Finally, Callan Family Office LLC raised its position in DexCom by 222.5% during the second quarter. Callan Family Office LLC now owns 23,832 shares of the medical device company’s stock valued at $2,080,000 after acquiring an additional 16,443 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Friday, August 15th. The shares were sold at an average price of $80.29, for a total transaction of $40,145.00. Following the sale, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Kyle Malady sold 667 shares of DexCom stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 over the last three months. 0.32% of the stock is currently owned by corporate insiders.

DexCom Trading Up 0.1%

NASDAQ:DXCM opened at $65.20 on Tuesday. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a market cap of $25.57 billion, a price-to-earnings ratio of 45.28, a P/E/G ratio of 1.37 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. The company’s 50 day moving average is $74.20 and its 200-day moving average is $77.70.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter last year, the company posted $0.43 earnings per share. DexCom’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. Robert W. Baird cut their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research report on Friday, September 26th. The Goldman Sachs Group cut their price objective on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Truist Financial initiated coverage on shares of DexCom in a research report on Monday, June 16th. They set a “buy” rating and a $102.00 price objective on the stock. Barclays lifted their price target on shares of DexCom from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 30th. Finally, Citigroup dropped their price target on shares of DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.42.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.